MRI with Gadolinium-Based Nanoparticles - Nanotechnology for Biomedical Imaging and Diagnostics - page 250

[114] Han L, Li J, Huang s, Huang R, Liu s, Hu X, Yi p, shan d, Wang X, Lei H.
peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1
magnetic resonance imaging contrast agent. Biomaterials 2011; 32 :2989-2998.
[115] Fossheim sL, Fahlvik AK, Klaveness J, Muller Rn. paramagnetic liposomes as MRI
contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity.
Magn Reson Imaging 1999; 17 :83-89.
[116] Løkling Ke, skurtveit R, Bjørnerud A, Fossheim sL. novel pH-sensitive paramagnetic
liposomes with improved MR properties. Magn Reson Med 2004; 51 :688-696.
[117] Kabalka G, davis M, Moss T, Buonocore e, Hubner K, Holmberg e, Maruyama K,
Huang L. Gadolinium-labeled liposomes containing various amphiphilic Gd-dTpA
derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson Med
1991; 19 :406-415.
[118] Tilcock C, Ahkong QF, Koenig sH, Brown Rd, davis M, Kabalka G. The design of
liposomal paramagnetic mr agents: effect of vesicle size upon the relaxivity of surface-
incorporated lipophilic chelates. Magn Reson Med 1992; 27 :44-51.
[119] storrs RW, Tropper Fd, Li HY, song CK, Kuniyoshi JK, sipkins dA, Li KC, Bednarski
Md. paramagnetic polymerized liposomes: synthesis, characterization, and applica-
tions for magnetic resonance imaging. J Am Chem soc 1995; 117 :7301-7306.
[120] Kielar F, Tei L, Terreno e, Botta M. Large relaxivity enhancement of paramagnetic lipid
nanoparticles by restricting the local motions of the gdiii chelates. J Am Chem soc
2010; 132 :7836-7837.
[121] schühle dT, van Rijn p, Laurent s, Vander elst L, Muller Rn, stuart MCA, schatz J,
peters JA. Liposomes with conjugates of a calix[4]arene and a Gd-dOTA derivative on
the outside surface; an efficient potential contrast agent for MRI. Chem Commun
(Camb) 2010; 46 :4399-4401.
[122] Gløgård C, Hovland R, Fossheim sL, Aasen AJ, Klaveness J. synthesis and physico-
chemical characterisation of new amphiphilic gadolinium dO3A complexes as contrast
agents for MRI. J Chem soc perkin Trans 2000; 2 :1047-1052.
[123] André Jp, Tóth É, Fischer H, seelig A, Mäcke HR, Merbach Ae. High relaxivity for
monomeric Gd (dOTA)-based MRI contrast agents, thanks to micellar self-organization.
Chem A eur J 1999; 5 :2977-2983.
[124] Trubetskoy Vs, Torchilin Vp. new approaches in the chemical design of Gd-containing
liposomes for use in magnetic resonance imaging of lymph nodes. J Liposome Res
1994; 4 :961-980.
[125] Winter pM, Caruthers sd, Yu X, song s-K, Chen J, Miller B, Bulte JWM, Robertson
Jd, Gaffney pJ, Wickline sA, Lanza GM. Improved molecular imaging contrast agent
for detection of human thrombus. Magn Reson Med 2003; 50 :411-416.
[126] Kok MB, de Vries A, Abdurrachim d, prompers JJ, Grüll H, nicolay K, strijkers GJ.
Quantitative 1H MRI, 19F MRI, and 19F MRs of cell-internalized perfluorocarbon
paramagnetic nanoparticles. Contrast Media Mol Imaging 2011; 6 :19-27.
[127] unger eC, Winokur T, Macdougall p, Rosenblum J, Clair M, Gatenby R, Tilcock C.
Hepatic metastases: liposomal Gd-dTpA-enhanced MR imaging. Radiology 1989; 171 :
81-85.
[128] Ayyagari AL, Zhang X, Ghaghada KB, Annapragada A, Hu X, Bellamkonda RV. Long-
circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson
Med 2006; 55 :1023-1029.